Genetics and molecular pathology of gastric malignancy: Development of targeted therapies in the era of personalized medicine

Michael Van Ness, Jeffrey Gregg, Jun Wang, Mingyi Chen

Research output: Contribution to journalReview article

9 Scopus citations


Gastric malignancy constitutes a major cause of cancer deaths worldwide. Despite recent advances in surgical techniques combined with neoadjuvant chemotherapy and radiotherapy approaches, patients with advanced disease still have poor outcomes. An emerging understanding of the molecular pathways that characterize cell growth, cell cycle, apoptosis, angiogenesis, invasion and metastasis has provided novel targets in gastric cancer therapy. In this review, recent advances in the understanding of molecular tumorigenesis for common gastric malignancies are discussed. We also briefly review the current targeted therapies in the treatment of gastric malignancies. Practical insights are highlighted including HER2 testing and target therapy in gastric adenocarcinoma, morphologic features and molecular signatures of imatinib-resistance GISTs, and recent investigations aimed at tumor-specific therapy for neuroendocrine tumors.

Original languageEnglish (US)
Pages (from-to)243-250
Number of pages8
JournalJournal of Gastrointestinal Oncology
Issue number3
Publication statusPublished - Jan 1 2012



  • Gastric malignancy
  • Genetics and molecular pathology
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this